Spots Global Cancer Trial Database for A Study of DeTIL-0255 in Adults With Advanced Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of DeTIL-0255 in Adults With Advanced Malignancies

Official Title: A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults With Advanced Malignancies

Study ID: NCT05107739

Conditions

Platinum-resistant Ovarian Cancer

Endometrial Cancer

Cervical Cancer

Interventions

Drug Product De-TIL-0255

Study Description

Brief Summary: This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.

Detailed Description: This study includes a safety run in and a cohort expansion. The safety run in will include patients with any of the indications under study including: Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma Recurrent, metastatic, or persistent cervical carcinoma Advanced or recurrent endometrial cancer Cohort expansion will include patients with advanced malignancies who have received at least two prior systemic therapies in the same indications.